A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
Oxomemazine, oxomemazinum, oxomemazine
Class :
Antiallerics/antihistamines
Brand Name :
N/A
Synonyms :
Oxomemazine, oxomemazinum, oxomemazine
Class :
Antiallerics/antihistamines
Dosage Forms & Strengths
Oral
2.5mg
5mg
20mg
5mg- 13 mg orally once a day in divided doses
5mg- 13 mg orally once a day in divided doses
Dosage Forms & Strengths
Oral
2.5mg
5mg
20mg
Children of age 0-3months:
2.5mg to 5mg once daily
Children of age more than three months:
5mg to 20mg once daily
Note: The dose needs to be taken as two to three divided doses
Children of age 0-3months:
2.5mg to 5mg once daily
Children of age more than three months:
5mg to 20mg once daily
Note: The dose needs to be taken as two to three divided doses
Refer to adult dosing
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
It may increase the CNS depressant effect when combined with CNS Depressants
oxomemazine: they may increase the hypotensive effect of blood viscosity reducing agents
oxomemazine: they may increase the hypotensive effect of blood viscosity reducing agents
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
may increase the CNS depressant effect of CNS Depressants
the therapeutic effects of droxidopa may be increased
the therapeutic effect of ephedrine may be increased
the therapeutic effect of epinephrine may be increased
the therapeutic effect of norepinephrine may be increased
the therapeutic effect of protokylol may be increased
the therapeutic effect of racepinephrine may be increased
Actions and spectrum:
Oxomemazine inhibits the pharmacological activity of histamine by competitively blocking H1-histamine receptors
Frequency not defined
Rashes
Photosensitivity
Dry mouth
Gynaecomastia
Urinary retention
Somnolence
Orofacial dyskinesia
Vertigo
Headache
Muscular hypotonia
Contraindication/Caution:
Contraindication:
Paralytic ileus
Status asthmaticus
Myasthenia
COPD
Pyloric stenosis
Prostatic adenoma
Angle-closure glaucoma
Pregnancy consideration:
USFDA pregnancy category: Not assigned
Lactation:
Data about the excretion of oxomemazine into breast milk is not known
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Oxomemazine is an antihistaminic drug with sedative property
Pharmacodynamics:
Oxomemazine belongs to a class of phenothiazines
Pharmacokinetics:
Limited data available
Absorption
Distribution
Metabolism
Elimination and excretion
Half-life:
Administration:
To be taken as per the advice of the physician
Patient information leaflet
Generic Name: oxomemazine
Why do we use oxomemazine?
Oxomemazine is an antihistaminic drug used in the treatment of allergic skin reactions. It is employed to relieve pruritis and hypersensitivity reactions. It also has few sedative and anticholinergic properties.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
